Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group

Wu, Lihteh; Acón, Dhariana; Berrocal, María H.; Gallego-Pinazo, Roberto; Dolz-Marco, Rosa; Roca, José A.; Maia, Maurício; Rojas, Sergio; Zas, Marcelo; Arévalo, J. Fernando; Chhablani, Jay

doi:10.1007/s10792-021-02077-5

Cited by 6 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wu et al retrospectively review the data of 102 CRVO patients treated with bevacizumab. 27 After 5 years, the mean visual acuity gain was 0.22 logMAR with an average of 10.6 injections. Baseline BCVA and duration of symptoms were described predictive factors for visual outcome.…”

Section: Discussionmentioning

confidence: 95%

Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions

Corazza

D'Alterio

Savastano

et al. 2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose retinal vein occlusion (RVO) is classified as either branch (BRVO) or central (CRVO) RVO. The gold standard treatment for macular oedema (MO) secondary to RVO is intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Our study aimed to compare ranibizumab and aflibercept outcomes over a maximum follow-up of five years. Methods this retrospective study assessed treatment-naïve RVO patients. Active disease was treated with three loading injections followed by a pro-re-nata (PRN) regimen of an anti-VEGF agent. Visual outcomes and injection frequency were analyzed, with patients stratified according to RVO subtype, anti-VEGF agent used, baseline vision, and age. Results 316 CRVO-affected eyes and 467 BRVO-affected eyes were analysed. Visual benefits between different treatments did not significantly differ, except in year 1 in ranibizumab-treated BRVO eyes. However, aflibercept-treated CRVO and BRVO eyes required significantly fewer injections during the follow up period. Furthermore, our results confirm that younger patients achieve better visual outcomes with fewer intravitreal injections. Overall, half of our patients did not require further injections after 1 year from diagnosis. Conclusion the results demonstrate that anti-VEGF treatment of RVO benefits vision for up to 5 years. Our findings are the first to suggest that compared to ranibizumab, fewer aflibercept injections may be required over five years follow up. Prospective randomised trials are needed to confirm this, alongside further attention to OCT scan features and the effect of patient demographics on treatment outcomes.

show abstract

Section: Discussionmentioning

confidence: 95%

Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions

Corazza

D'Alterio

Savastano

et al. 2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The Pan‐American Collaborate Retinal Study group (PACORES) performed a multicentre retrospective case series of 102 eyes treated with bevacizumab for MO due to CRVO and reported a mean gain of 0.22 LogMAR letters (approximately nine letters) at 5 years. Eyes with better baseline BCVA and shorter duration of symptoms were more likely to achieve better BCVA 26 . The LUMINOUS study 25 reported visual improvement in CRVO eyes treated with ranibizumab at 1 year in routine clinical practice (+10.8 letters; SD19.7).…”

Section: Resultsmentioning

confidence: 99%

“…Eyes with better baseline BCVA and shorter duration of symptoms were more likely to achieve better BCVA. 26 The LUMINOUS F I G U R E 2 Meta-analysis 1-Visual outcomes for central retinal vein occlusion (CRVO) randomised controlled trials (RCT).…”

Section: Treatment Timingmentioning

confidence: 99%

Management of macular oedema due to retinal vein occlusion: An evidence‐based systematic review and meta‐analysis

Cornish

Zagora

Spooner³

et al. 2023

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Background Central retinal vein occlusion and branch retinal vein occlusion are common causes of visual loss due to associated macular oedema. The aim of this review was to assess the effectiveness of interventions improving vision and treating macular oedema in central retinal vein occlusion and branch retinal vein occlusion. Methods Medical search engines and clinical trial registries were systematically searched. Randomised clinical trials with ≥90 eyes and real‐world outcome studies with ≥100 eyes each with ≥6 months follow‐up were included. Results There were 11 randomised controlled trials evaluating treatments for central retinal vein occlusion which met the inclusion criteria and 10 for branch retinal vein occlusion. There were 10 real world outcome studies of central retinal vein occlusion and 5 real world outcome studies of branch retinal vein occlusion. Meta‐analysis was performed on studies that met the defined inclusion criteria. Main outcomes were change in visual acuity at 6‐, 12‐, 24‐ and 36 months by treatment. Conclusions Intravitreal anti‐vascular endothelial derived growth factor is recommended as first line treatment over intravitreal corticosteroid due to its effectiveness and lower rate of ocular adverse events. Best outcomes are achieved when intravitreal treatment is started early. Macular laser may have an adjunctive role in branch retina vein occlusion but not central retinal vein occlusion.

show abstract

“…Bevacizumab is a humanized monoclonal antibody that specifically binds to the VEGF-A protein [ 134 ]. Recently, its use by intravitreal administration in patients with central retinal vein occlusions (CRVO) improved best-corrected visual acuity (BCVA) and reduced the degree of cystoid macular edema (CME) after a 5-year treatment period [ 135 ]. Aflibercept is a fusion protein with high VEGF affinity attributed to binding sequences from the native receptors VEGFR1 and VEGFR2 [ 136 ].…”

Section: The Anti-angiogenic Modulatory Effect Of Resveratrolmentioning

confidence: 99%

Resveratrol: Its Path from Isolation to Therapeutic Action in Eye Diseases

et al. 2022

View full text Add to dashboard Cite

Due to the confirmed therapeutic potential of resveratrol (Rv) for eye diseases, namely its powerful anti-angiogenic and antioxidant effects, this molecule must be studied more deeply. Nowadays, the pharmaceutic and pharmacokinetic available studies offer a troubling picture because of its low stability and bioavailability. To overcome this problem, researchers started to design and create different delivery systems that could improve the delivery amount of Rv. Therefore, this review aims to shed light on the proper and efficient techniques to isolate, purify and quantify the Rv molecule, and how this therapeutic molecule can be a part of a delivery system. The Rv great impact on aspects regarding its stability, bioavailability and absorption are also debated here, based on the existent literature on in vitro and in vivo human and animal studies. Moreover, after its absorption the Rv influence at the molecular level in ocular pathologies is described. In addition, the present review summarizes the available literature about Rv, hoping that Rv will gain more attention to investigate its unexplored side.

show abstract

Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group

Cited by 6 publications

References 33 publications

Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions

Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions

Management of macular oedema due to retinal vein occlusion: An evidence‐based systematic review and meta‐analysis

Resveratrol: Its Path from Isolation to Therapeutic Action in Eye Diseases

Contact Info

Product

Resources

About